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Abstract
Background: It is unknown whether statin use among people living with HIV results in a reduction in all-cause
mortality. We aimed to evaluate the effect of statin use on all-cause mortality among people living with HIV.
Methods: We conducted comprehensive literature searches of Medline, Embase, CINAHL, the Cochrane Library, and
cross-references up to April 2018. We included randomised, quasi-randomised trials and prospective cohort studies
that examined the association between statin use and cardio-protective and mortality outcomes among people
living with HIV. Two reviewers independently abstracted the data. Hazard ratios (HRs) were pooled using empirical
Bayesian random-effect meta-analysis. A number of sensitivity analyses were conducted.
Results: We included seven studies with a total of 35,708 participants. The percentage of participants on statins
across the studies ranged from 8 to 35%. Where reported, the percentage of participants with hypertension ranged
from 14 to 35% and 7 to 10% had been diagnosed with diabetes mellitus. Statin use was associated with a 33%
reduction in all-cause mortality (pooled HR = 0.67, 95% Credible Interval 0.39 to 0.96). The probability that statin use
conferred a moderate mortality benefit (i.e. decreased risk of mortality of at least 25%, HR≤ 0.75) was 71.5%. Down-
weighting and excluding the lower quality studies resulted in a more conservative estimate of the pooled HR.
Conclusion: Statin use appears to confer moderate mortality benefits in people living with HIV.
Keywords: Statin, HIV, Mortality
Background
Although life expectancy for people living with HIV has
improved dramatically over the past two decades follow-
ing the introduction of highly active antiretroviral
therapy, mortality rates remain higher than in the gen-
eral population [1, 2]. As life expectancy has increased,
the incidence of non-communicable diseases (NCDs)
including cardio-metabolic disorders has also dispropor-
tionately increased along with risky behaviours such as
smoking, and has been identified as a major cause of ex-
cess mortality [3]. Dyslipidaemias are perhaps the most
common and most studied cardio-metabolic disorders
affecting people with HIV [4]. There are strong reasons
to hypothesise that statins are effective in reducing
cardiovascular events in people living with HIV. First,
they are effective in many groups and among high-risk
people who do not have HIV [5–17]. Second, they have
been shown to reduce dyslipidaemia in HIV-infected
people [18]. Third, they have been shown to act
anti-inflammatory agent [19, 20] and improve surrogate
markers for cardiovascular events, such as carotid
intima-media thickness [21] and coronary artery plaque
volume in people living with HIV [22].
Although studies of statins in HIV have evaluated
subclinical CVD, none has evaluated associations
between statin use and hard CVD endpoints. This
includes nonfatal CVD events such as MI and stroke as
well as CVD mortality. Thus, the logical next step would
be to evaluate statin use and hard CVD endpoints for
HIV+ persons. To date, no randomised trials have been
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published on this topic. However, analyses of hard CVD
endpoints, including CVD mortality, may be underpow-
ered due to insufficient data on hard CVD endpoints
and/or cause-specific mortality in HIV+ cohorts and
trial registries where statin use was assessed. As a result,
this study sought to leverage the best currently available
data and primarily evaluate overall mortality among HIV
+ persons taking vs. not taking statins, with the evalu-
ation of CVD mortality as an exploratory analysis.
Evidence regarding the potential benefits of a particular
intervention is often available from a variety of disparate
sources. When considering the benefit of an intervention
- particularly in the absence of any RCTs addressing the
relevant question - that ‘real-world’ evidence from
non-randomized studies should also be considered [23].
We aimed to examine whether statin use is associated
with all-cause mortality using a systematic review and
meta-analysis of prospective cohort studies.
Methods
Eligibility criteria
To be included, studies had to meet the following
selection criteria:
Types of studies: Randomised, quasi-randomised trials
and prospective cohort studies.
Types of participants: adult (> 18 years) people living
with HIV (PLHIV) of either sex.
Types of intervention: Any form of statin use regardless
of indication, including but not limited to primary or
secondary prevention of cardiovascular disease.
Types of comparator: no statin or placebo
Types of outcome measures: All-cause mortality.
Information sources and search strategy
We conducted a thorough literature search to identify
relevant studies. We searched electronic databases of
Medline, CINAHL and Web of Science from 1980 to
April 2018 without applying any language restriction. We
searched for abstracts of relevant conference proceedings
from the National Library of Medicine Gateway. In
addition, the bibliographies of retrieved articles were
examined for pertinent studies. The full Medline search
strategy is shown in Additional file 1: Appendix S1.
Study selection and data extraction
Two authors (OU and NC) evaluated the eligibility of
studies obtained from the literature search using a
predefined protocol and worked independently to scan
all abstracts and obtain the full texts of each selected
article. For each included study, details on design,
population characteristics, intervention and outcome
measures were extracted, and risk of bias was evaluated.
Any discrepancies between the authors were resolved
through discussion and involving a third author. Two
authors (OU and NC) independently extracted data.
Risk of bias assessment
We used the Cochrane tool Risk Of Bias In Non-rando-
mised Studies - of Interventions (ROBINS-I) to assess
the risk of bias of included studies (see Additional file 1:
Appendix S2) [24]. We assessed risks of bias in the
following seven domains, facilitated by consideration of
pertinent “signalling” questions, bias due to: confound-
ing, selection of participants, measurement of interven-
tions, departures from intended interventions, missing
data, measurement of outcomes, selection of reported
results. Within each domain, we rated risk of bias as
“low” (comparable to a well performed randomised trial),
“moderate” (sound for an observational study), “high”
(there are important problems), or “very high” (the study
is too problematic to provide useful evidence). The judge-
ments within each domain were carried forward to an
overall risk of bias judgement across bias domains.
Statistical analysis
For the main analysis, we performed Bayesian random-
effects meta-analysis [25] with a prior based on expected
heterogeneity to pool the hazard ratio (HR) estimates for
the association between statin use and all-cause mortal-
ity among studies [26]. We selected random-effects
meta-analysis on account of anticipated heterogeneity in
study population and methodology [26]. Treatment
effect measures, the hazard ratio and odds ratio were log
transformed to reduce skewness. We combined hazard
ratio (HR) and odds ratio (OR) in the meta-analysis. HR
and OR can be interpreted similarly if the underlying as-
sumption of a generally low event risk (< 20%) is true [27].
We performed a meta-regression analysis to explore
the relationship between the following study-level factors
and reported treatment effects: sample size, publication
year, cohort follow-up period, percentage of statin use,
percentage male, mean age and study location (Europe
vs. North America). Given the low number of studies
identified in the study univariate meta-regressions were
estimated as opposed to multivariate. All models were
estimated using STAN and R [28].
Sensitivity analyses
A number of sensitivity analyses were conducted to
examine the robustness of the results to study quality and
modelling assumptions. First, we assigned ‘quality weights’
to the studies on the basis of the risk of bias assessment
[29]. The quality weights can be interpreted as the propor-
tion of variance of a studies results not attributable to bias.
Two sets of weights were used: (i) studies at high risk of
bias were assigned a weight of 20% and studies at a
moderate/low risk were assigned a weight of 70%; (ii) the
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respective weights for high risk and low/moderate risk
were 50 and 80%. Second, we re-estimated the model
excluding studies deemed as being at high risk of bias (a
quality weight of zero). Third, we examined the sensitivity
of the results to the choice of prior distribution. We used
an informative ‘sceptical’ prior distribution based on the
principle that ‘Most clinically important interventions are
likely to reduce the relative risk of all-cause mortality by
about 10-20%.’ The sceptical prior specifies that there was
only a 5% probability that the HR was less than 0.75 [30].
This systematic review was reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines [31] (Additional file 1:
Appendix S3).
Results
Study selection and characteristics
The process of study selection is shown in Fig. 1. Over-
all, the literature searches of databases yielded 615
articles. After review of abstracts and titles, 11 articles
were selected for critical reading. Four studies did not
meet the inclusion criteria [32–35] as no relevant
outcomes were reported. Seven studies with a total of
35,708 participants were included [36–42]. The charac-
teristics of the included studies are shown in Table 1.
The studies were conducted between 1995 and 2015 and
published between 2011 and 2015. Five were reported as
full-text journal articles [38–42], and two were presented
as conference abstracts [36, 37]. All the studies were
from high-income countries; four from the USA. The
other studies were conducted in Denmark, France and
Spain. The median number of participants was 1738 and
ranged from 438 to 25,884. All the seven studies were
cohort studies [36–42]. The mean age at entry of the
participants ranged from 39 to 51 years and the propor-
tions of males included in the studies ranged from 67%
to as much as 98% (from US Veterans Affairs’ Clincial
Case Registry). The percentage of participants on statins
Fig. 1 PRISMA Flow for study selection
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across the studies ranged from 8 to 35%. None of the
study reported statin type. When reported, the percent-
age of participants with hypertension ranged from 14 to
35% and 7 to 10% had been diagnosed with diabetes
mellitus. None of the studies reported rates of adherence
to statins use.
Quality assessment of included studies
A summary of the risk of bias assessment in the
included studies is shown in Additional file 1: Table S1.
The risk of bias due to confounding was moderate all
the seven studies. The bias in selection of participants
was moderate in four studies [36, 38, 41, 42] and serious
in three studies [37, 39, 40] For Knobel and colleagues
study [37], the Framingham cardiovascular risk score
above 20% was significantly higher among those on
statin compared with those not on statins (21.4% versus
5.0%, RR = 2.95, 95% CI 2.22 to 3.92) and those on statin
had significantly higher median total cholesterol (231
versus 178 mg/dL). Similarly, for Lang et al. [39], the
proportion of participants with hypertension (29.7%
versus 12.4%) and type 2 diabetes mellitus (21.7% versus
9.1%) was significantly higher among those exposed to
statins compared with those not on statins at baseline.
For Moore and colleagues study [40], the proportion of
participants on antihypertensive medications was signifi-
cantly higher among those on statin compared with
those not on statins (46.3% versus 25.6%). The bias in
measurement of interventions due to departures from
intended interventions and due to missing data were
moderate all the seven studies. The bias in measurement
of outcomes was low in all studies, because the outcome
of study was death ascertained via adequate record
linkages [36–42]. The bias in selection of reported
studies was rated serious in the two studies published as
conference abstracts [36, 37] and moderate in the
remaining five studies. Overall risk of bias was moderate
in three studies and serious in four studies.
Effects of statins on all-cause mortality
The Bayesian random-effects meta-analysis yielded a
pooled HR of 0.67 (95% CrI 0.39 to 0.96) in the risk of
all-cause mortality; a 33% reduction in absolute risk
(Fig. 2). However, 95% prediction interval for the pooled
HR contains values greater than 1 (0.21 to 1.76), which
suggests that although on average statins seem to be
effective in reducing all-cause mortality, not all future
individual studies can be expected to show all-cause
mortality benefits of statins.
Table 2 and Additional file 1: Table S2 reports the
estimated pooled HRs from the sensitivity analyses.
Down-weighting the lower quality studies resulted in a
more conservative estimate of the pooled HR. The
pooled HRs from the two weighting schemes were 0.82
(0.49, 1.35) and 0.76 (0.50, 1.13). Excluding low quality
also resulted in a more conservative estimate of the
pooled HR. The ‘sceptical’ prior resulted in a posterior
mean estimate of the pooled HR of 0.88 (0.69, 1.14).
In a series of meta-regression analyses, none of the
study level factors were associated with treatment effect
estimates (Table 3).
Only two studies [37, 40] reported cardiovascular
disease mortality as an outcome. The pooled HR from
these two studies was 1.23 (0.52, 2.61). Only two studies
[36, 41] reported cardiovascular disease event rates as
on outcome. The pooled HR was 0.69 (0.37, 1.62).
Discussion
Main findings
To our knowledge, this systematic review and meta-ana-
lysis, comprising seven observational studies with more
than 35,000 HIV-infected participants, is the first to
examine the effect of statin therapy on all-cause
mortality in people living with HIV. Overall, the findings
support the expectation that statins confer mortality
benefit. However, due to the limited evidence currently
available, we can draw no conclusions as to effectiveness
of statins on cardiovascular disease mortality and
Fig. 2 Forest plot of association between statins use and all-cause mortality
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cardiovascular events. Nevertheless, the results of our
meta-analysis usefully extend previously published
meta-analyses of statin use in other high-risk groups
such as the recent pivotal collaborative meta-analysis of
individual participants’ data by the Cholesterol Treat-
ment Trialists’ (CTT) [7] based on 174, 000 individuals,
that reported reductions of approximately 10% in
all-cause mortality for both women (risk ratio, 0.91; 99%
CI 0.84–0.99) and men (risk ratio, 0.90, 99% 0.86–0.95).
However, there has been conflicting literature about the
association of statin use with all-cause mortality in other
population [11, 13]. Ray and colleagues conducted a
meta-analysis of 11 RCTs involving 65,2229 participants
to examine the effect of statin use on all-cause mortality
among intermediate to high-risk individuals without a
history of CVD [11]. They found that the use of statins
in this high-risk primary prevention setting was not
associated with a statistically significant reduction (risk
ratio, 0.91; 95% confidence interval, 0.83–1.01) in the
risk of all-cause mortality [11]. Taylor and colleagues
conducted Cochrane review to assess the effects, both
harms and benefits, of statins in in adults with no
restrictions on total, low density lipoprotein (LDL) or
high-density lipoprotein (HDL) cholesterol levels, and
where 10% or less had a history of CVD [13]. They
included 18 RCTs involving 56,934 participants and found
that all-cause mortality was reduced by statins (odds ratio
0.86, 95% confidence interval, 0.79 to 0.94) [13].
PLHIV are now living longer than because of effective
treatment with antiretroviral therapy [43]. However, the
increased life expectancy is now associated with in-
creased prevalence of chronic conditions such as
cardiovascular disease [43]. It has now been documented
in the literature that PLHIV are at increased risk of
developing CVD than non-HIV patients [43–45]. In
addition, there is disparities in the quality of CVD care
between PLHIV and uninfected adults [46]. Ladapo and
colleagues found that “Physicians generally underused
guideline-recommended cardiovascular care and were
less likely to prescribe aspirin and statins to HIV-infected
patients at increased risk-findings that may partially
explain higher rates of adverse cardiovascular events
among patients with HIV”. [46] Implementation of
intensive lifestyle modification in PLHIV may help reduce
CVD mortality and morbidity [43]. The frequency and
consistency of clinical encounters with PLHIV may
provide a unique opportunity to provide them with con-
tinuous assistance to help behaviour changes to prevent
CVD risk [43]. Given the crucial need for prevention of
cardiovascular disease in PLHIV, there is a need for a
multi-morbidity trials to definitively assess the efficacy of
statins as a primary prevention strategy for cardiovascular
disease in this at-risk population [47, 48], especially in
resource-limited settings that bear the highest burden of
HIV. Furthermore, low income settings are now experien-
cing an epidemiological transition from infectious diseases
to chronic diseases, [49] as a result of dramatic changes in
diet and lifestyle. The epidemiological transition in LMICs
is happening over a shorter time frame than that experi-
enced historically by high-income countries [50].
Study limitations and strengths
Strengths of this study include the comprehensive
searches of databases to ensure that all relevant, published
studies were identified. We used a Bayesian approach that
allows us to utilize informative prior information. The
main limitation of our study is that the nature of the
literature is entirely observational. Statistical adjustment
cannot exclude existing confounding, such as confounding
by indication or variations in other patient or clinician
level variability that might be independently associated
with the outcome. Counter-intuitively, there is some
evidence that statin may increase risk of CVD mortality,
but perhaps not surprising because it likely reflects some
confounding by therapy indication - people prescribed
statins may be more likely to have pre-existing CVD or be
at greater risk for CVD, and this risk is unlikely to be fully
Table 2 Estimated pooled HRs from the sensitivity analyses
Posterior mean (95% CrI) Number of studies I2 Probability HR < 1
Main analysis 0.67 (0.39, 0.96) 7 63% 97%
Down-weight low quality studies (20%/70%)a 0.82 (0.49, 1.35) 7 49% 80%
Down-weight low quality studies (50%/80%)b 0.76 (0.50, 1.13) 7 43% 92%
Exclude low quality studies 0.81(0.49, 1.37) 4 45% 81%
‘Sceptical’ prior 0.88 (0.69, 1.14) 7 62% 85%
Table 3 Study level factors associated with treatment effect
estimates, meta-regression analyses
Factor Ratio of Hazard Ratio
(95% Credible Interval)
Sample size (per 1000 people) 1.02 (0.97 to 1.06)
Publication year 1.20 (0.85 to 1.71)
Cohort follow-up period 1.16 (0.93 to 1.38)
Statin use (%) 1.01 (0.95 to 1.06)
Male (%) 1.02 (0.98 to 1.05)
Age (mean, years) 1.08 (0.98 to 1.18)
Europe vs. North America studies 0.94 (0.31 to 2.27)
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accounted for through multivariable adjustment. Thus,
factors leading to these people being prescribed statins
may be responsible for their apparently elevated CVD-
related mortality rather than their actual use of statins.
Statins are a large constellation with different results
depending upon the type and dose of statin therapy. As
these data were not reported, it was not possible to
conduct sensitivity analyses to stratify by different types
and doses of statins. In addition, the pooled association
should be interpreted with caution because it is derived
from observational studies. Our study found high I2 values
as measures of heterogeneity. However, it is worth noting
that the I2 measurement offers inflated estimates when
dealing with non-comparative studies. Meta-regression
analyses are prone to ecological fallacy (aggregate bias)
and may have low power to detect an association [51–53].
We did not conduct tests for publication bias because we
included observational studies and we are aware that
many patients outside these studies receive statin
treatment, so there is, by definition, publication bias.
Finally, the fact that most included studies were
observational may explain a larger treatment effect
observed in our analysis than that observed among
RCTs in non-HIV patients [7].
Conclusions
In summary, based on pooled data on 35,708 HIV-infected
participants from seven observational studies, we observed
that statin therapy may have an important mortality benefit
in people living with HIV, accounting for an estimated 33%
reduction in all-cause mortality. While awaiting a definitive
answer from on-going trials and long-term observational
studies about the benefits of statin as a primary prevention
for cardiovascular disease and all-cause mortality, our
findings are timely and reassuring. They reinforce the
notion that lowering lipid levels is likely to be associated
with a reduction in all-cause mortality in people living with
HIV as it is in other high-risk groups.
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